The biopharmaceutical trade faces headwinds from the Trump administration’s ongoing tariffs and drug pricing pressures within the US. Consequently, the highest 20 international biopharmaceutical firms have reported a downturn of 5.7% of their mixed market capitalisation, from $3.92 trillion on 31 March 2025 to $3.70 trillion on 30 June 2025, in accordance with main knowledge analytics and analysis firm, GlobalData.
Alnylam witnessed the biggest market capitalisation progress, up 21.8% to $42.5 billion, and secured a spot as a brand new entrant within the high 20 gamers. The corporate’s progress was largely pushed by the robust efficiency of its RNA interference (RNAi) therapeutic Amvuttra for transthyretin amyloidosis cardiomyopathy (ATTR-CM), which noticed a 59% year-on-year (YoY) enhance in international gross sales to $310 million within the first quarter (Q1) 2025.
Novartis reported a 7.7% enhance in market capitalisation in Q2 2025 as a consequence of robust monetary efficiency, with blockbuster drug gross sales progress, together with Entresto, Cosentyx, Kesimpta and Kisqali in 2024. The acquisition of Regulus Therapeutics in June 2025, valued at $1.7 billion, strengthens Novartis’ renal illness portfolio. The acquisition contains farabursen, an miRNA17-targeting antisense oligonucleotide, as a consequence of enter pivotal Part III trials in Q3 2025, with constructive outcomes for its Part Ib MAD research in polycystic kidney illness introduced in March 2025.
Nonetheless, the bulk (16) of the highest 20 gamers registered a lower in market capitalisation in Q2 2025. Bristol Myers Squibb noticed the biggest market capitalisation decline of twenty-two.9%, following the announcement of a blended Q1 2025 monetary efficiency and detrimental trial outcomes. Notably, the corporate’s Part III ARISE trial investigating Cobenfy as an adjunctive remedy to atypical antipsychotics for schizophrenia didn’t meet its main endpoint of change within the Constructive and Detrimental Syndrome Scale (PANSS).
Regeneron at -18.7% and Sanofi at -13.8% noticed declines in market capitalisation because of the failure of itepekimab, their partnered IL-33-targeting monoclonal antibody, to fulfill its main endpoint within the Part III AERIFY-2 trial, which aimed to attain a discount in reasonable or extreme exacerbations of persistent obstructive pulmonary illness. This represents a setback for itepekimab since Sanofi deliberate to file for US and EU regulatory approval within the second half of 2025. Nonetheless, analyst consensus forecasts itepekimab to attain international gross sales exceeding $1 billion by 2031, in accordance with GlobalData’s Gross sales and Forecast database.